Soleno Therapeutics (NASDAQ:SLNO) Trading Up 10% – Here’s What Happened

Soleno Therapeutics, Inc. (NASDAQ:SLNO)’s share price was up 10% on Tuesday . The stock traded as high as $32.81 and last traded at $33.48. Approximately 147,595 shares were traded during trading, a decline of 91% from the average daily volume of 1,587,466 shares. The stock had previously closed at $30.44.

Soleno Therapeutics News Summary

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Unusually heavy call buying — investors purchased about 2,940 call options today (≈+49% vs. the average of 1,968), signaling short-term bullish speculative activity that likely contributed to the stock’s intraday rise.
• Negative Sentiment: A new securities class action has been filed against Soleno alleging claims for purchases during March 26, 2025–August 4, 2025; a formal complaint increases litigation exposure and potential future financial/settlement risk. SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Soleno Therapeutics, Inc. (SLNO)
• Negative Sentiment: Hagens Berman and other firms tie the suits to Soleno’s November 2025 disclosures about DCCR (VYKAT XR) launch disruptions — the substantive allegation (management concealed drug risks) amplifies reputational and regulatory scrutiny. Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions — Hagens Berman
• Negative Sentiment: Multiple plaintiff firms (Rosen, Faruqi & Faruqi, Gross, Glancy, Portnoy, Levi & Korsinsky, etc.) are issuing investor alerts and May 5, 2026 lead‑plaintiff deadline reminders — increased publicity raises the chance of consolidated litigation and settlement pressure. ROSEN, A TOP RANKED LAW FIRM, Encourages Soleno Therapeutics Inc. Investors to Secure Counsel

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on SLNO shares. Robert W. Baird set a $107.00 price objective on Soleno Therapeutics in a research note on Tuesday, January 13th. Wolfe Research set a $60.00 price target on shares of Soleno Therapeutics in a report on Monday, January 12th. TD Cowen reduced their price target on shares of Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Wells Fargo & Company decreased their price objective on shares of Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating for the company in a research note on Friday, February 27th. Finally, Oppenheimer dropped their price objective on shares of Soleno Therapeutics from $110.00 to $80.00 and set an “outperform” rating on the stock in a report on Wednesday, March 18th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $102.00.

Soleno Therapeutics Trading Up 12.2%

The firm has a market cap of $1.76 billion, a price-to-earnings ratio of 150.40 and a beta of -3.16. The company has a fifty day moving average price of $38.28 and a 200-day moving average price of $48.24. The company has a current ratio of 5.80, a quick ratio of 5.55 and a debt-to-equity ratio of 0.11.

Soleno Therapeutics (NASDAQ:SLNO) last posted its earnings results on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.64 by $0.16. The company had revenue of $91.73 million for the quarter, compared to analyst estimates of $88.55 million. As a group, research analysts expect that Soleno Therapeutics, Inc. will post -3.72 EPS for the current year.

Hedge Funds Weigh In On Soleno Therapeutics

Several institutional investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Soleno Therapeutics by 1.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock worth $1,242,000 after purchasing an additional 189 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Soleno Therapeutics in the second quarter valued at approximately $25,000. Avanza Fonder AB raised its stake in shares of Soleno Therapeutics by 11.2% during the 4th quarter. Avanza Fonder AB now owns 3,195 shares of the company’s stock worth $148,000 after buying an additional 323 shares during the period. Principal Financial Group Inc. lifted its position in shares of Soleno Therapeutics by 11.9% during the 3rd quarter. Principal Financial Group Inc. now owns 3,197 shares of the company’s stock valued at $216,000 after buying an additional 340 shares in the last quarter. Finally, New York State Common Retirement Fund lifted its position in shares of Soleno Therapeutics by 2.4% during the 3rd quarter. New York State Common Retirement Fund now owns 15,600 shares of the company’s stock valued at $1,055,000 after buying an additional 360 shares in the last quarter. 97.42% of the stock is owned by hedge funds and other institutional investors.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.